Christopher R. Bowie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher R. Bowie has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Philip D. Harvey
Department of Psychiatry, Mt. Sinai School of Medicine, 1425 Madison Ave, 4th Floor, Box 1230, New York, NY 10029, USA
8 shared publicationsAbraham Reichenberg
Department of Psychiatry, Mt. Sinai School of Medicine, 1425 Madison Ave, 4th Floor, Box 1230, New York, NY 10029, USA
3 shared publicationsThomas L. Patterson
Department of Psychiatry UCSD Medical Center
3 shared publications- Margaret McNamara McClure
Fairfield University
2 shared publications Philip D Harvey
2 shared publications- Philip D. Harvey
University of Miami
2 shared publications
Latest Publications
- 1 August 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 103 (1-3) , 240-247
Communication abnormalities predict functional outcomes in chronic schizophrenia: Differential associations with social and adaptive functions
- 1 August 2008
- Published by Elsevier in Schizophrenia Research
- Vol. 103 (1-3) , 240-247
Communication abnormalities predict functional outcomes in chronic schizophrenia: Differential associations with social and adaptive functions
- Top Cited Papers
- 1 March 2008
- Published by Elsevier in Biological Psychiatry
- Vol. 63 (5) , 505-511
Predicting Schizophrenia Patients’ Real-World Behavior with Specific Neuropsychological and Functional Capacity Measures
- 1 March 2008
- Published by Elsevier in Biological Psychiatry
- Vol. 63 (5) , 505-511
Top Cited PapersPredicting Schizophrenia Patients’ Real-World Behavior with Specific Neuropsychological and Functional Capacity Measures
- 1 December 2007
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 41 (12) , 1012-1018
Self-assessment of functional status in schizophrenia
- 1 December 2007
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 41 (12) , 1012-1018
Self-assessment of functional status in schizophrenia
- 1 March 2007
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 7 (3) , 281-287
Methods for treating cognitive deficits in schizophrenia
Studies from the molecular to clinical level suggest that cognitive dysfunction is central in characterizing schizophrenia. Accordingly, there have been increased efforts to search for effective treatments of these broad and debilitating cognitive deficits. Three general strategies for treating cognitive dysfunction in schizophrenia have emerged in the literature. The second-generation (atypical) antipsychotic medications have received much attention but their procognitive effects tend to be modest. Augmentation strategies, driven from basic science or translational research, have often been promising in small uncontrolled trials; however, few agents have fared well in rigorously designed trials. Behavioral interventions have demonstrated positive effects that generalize to other symptom domains and persist after the intervention, but tend to be costly and labor intensive. Thus, although there have been some exciting advances in treating cognitive dysfunction, the gains to date are modest and the search for treatment methods continues.
- 1 March 2007
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 7 (3) , 281-287
Methods for treating cognitive deficits in schizophrenia
Studies from the molecular to clinical level suggest that cognitive dysfunction is central in characterizing schizophrenia. Accordingly, there have been increased efforts to search for effective treatments of these broad and debilitating cognitive deficits. Three general strategies for treating cognitive dysfunction in schizophrenia have emerged in the literature. The second-generation (atypical) antipsychotic medications have received much attention but their procognitive effects tend to be modest. Augmentation strategies, driven from basic science or translational research, have often been promising in small uncontrolled trials; however, few agents have fared well in rigorously designed trials. Behavioral interventions have demonstrated positive effects that generalize to other symptom domains and persist after the intervention, but tend to be costly and labor intensive. Thus, although there have been some exciting advances in treating cognitive dysfunction, the gains to date are modest and the search for treatment methods continues.
- Open Access
- 1 December 2006
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 2 (4) , 531-536
Cognitive deficits and functional outcome in schizophrenia
Cognitive dysfunction is a core feature of schizophrenia. Deficits are moderate to severe across several domains, including attention, working memory, verbal learning and memory, and executive functions. These deficits pre-date the onset of frank psychosis and are stable throughout the course of the illness in most patients. Over the past decade, the focus on these deficits has increased dramatically with the recognition that they are consistently the best predictor of functional outcomes across outcome domains and patient samples. Recent treatment studies, both pharmacological and behavioral, suggest that cognitive deficits are malleable. Other research calls into question the meaningfulness of cognitive change in schizophrenia. In this article, we review cognitive deficits in schizophrenia and focus on their treatment and relationship to functional outcome.
- 1 December 2006
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 2 (4) , 531-536
Open AccessCognitive deficits and functional outcome in schizophrenia
Cognitive dysfunction is a core feature of schizophrenia. Deficits are moderate to severe across several domains, including attention, working memory, verbal learning and memory, and executive functions. These deficits pre-date the onset of frank psychosis and are stable throughout the course of the illness in most patients. Over the past decade, the focus on these deficits has increased dramatically with the recognition that they are consistently the best predictor of functional outcomes across outcome domains and patient samples. Recent treatment studies, both pharmacological and behavioral, suggest that cognitive deficits are malleable. Other research calls into question the meaningfulness of cognitive change in schizophrenia. In this article, we review cognitive deficits in schizophrenia and focus on their treatment and relationship to functional outcome.
- 1 July 2006
- Vol. 7 (7) , 608-13
Treatment of cognitive deficits in schizophrenia.
Cognitive deficits are a core feature of schizophrenia and are a major contributor to functional disability. These impairments persist even when patients are in remission of psychotic symptoms and have, to date, eluded treatment. While some improvement is noted with existing medications, current trends in this field include studying and searching for adjunctive treatments to truly remediate cognitive dysfunction in schizophrenia. Psychosocial treatments have demonstrated some success, but the use of existing cognitive enhancers in schizophrenia treatment has provided little cognitive improvement. This paper reviews the current status of cognitive deficit treatment in schizophrenia and offers suggestions for future work.
- 1 July 2006
- Vol. 7 (7) , 608-13
Treatment of cognitive deficits in schizophrenia.
Cognitive deficits are a core feature of schizophrenia and are a major contributor to functional disability. These impairments persist even when patients are in remission of psychotic symptoms and have, to date, eluded treatment. While some improvement is noted with existing medications, current trends in this field include studying and searching for adjunctive treatments to truly remediate cognitive dysfunction in schizophrenia. Psychosocial treatments have demonstrated some success, but the use of existing cognitive enhancers in schizophrenia treatment has provided little cognitive improvement. This paper reviews the current status of cognitive deficit treatment in schizophrenia and offers suggestions for future work.
- 1 June 2006
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 57 (6) , 838-843
Convergence of Clinical Staff Ratings and Research Ratings to Assess Patients With Schizophrenia in Nursing Homes
A large number of older patients with serious mental illnesses, including schizophrenia, now reside in nursing homes or similar residences, yet little is known about assessments, services, or outcomes for these patients. The Minimum Data Set (MDS) is a mandatory assessment instrument for nursing care facilities, and although it has been well studied in the general nursing home population, little is known about its validity in assessing schizophrenia, which was the purpose of this study. A group of 77 patients with schizophrenia had been recruited as part of a longitudinal study and were evaluated after their referral to nursing homes. Researchers compared ratings from the MDS with ratings of cognition and symptoms using instruments previously validated for the assessment of serious mental illness. The cognitive subscale of the MDS (MDS-COG) was not strongly correlated with the Mini-Mental State Examination and was generally uncorrelated with performance on neuropsychological tasks. Symptoms were underreported on the MDS and were not significantly associated with researchers' ratings. Moreover, the ratings from the MDS, unlike the researchers' ratings, were not predictive of functional status, revealing poor criterion validity. These findings suggest that the MDS is not a suitable rating instrument to evaluate the symptoms and functional characteristics of older patients with schizophrenia. Future work will be required to develop instruments that would allow nursing home staff to recognize and report symptoms, cognitive impairments, and functional characteristics of these patients, which are important first steps for improving treatment services.
- 1 June 2006
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 57 (6) , 838-843
Convergence of Clinical Staff Ratings and Research Ratings to Assess Patients With Schizophrenia in Nursing Homes
A large number of older patients with serious mental illnesses, including schizophrenia, now reside in nursing homes or similar residences, yet little is known about assessments, services, or outcomes for these patients. The Minimum Data Set (MDS) is a mandatory assessment instrument for nursing care facilities, and although it has been well studied in the general nursing home population, little is known about its validity in assessing schizophrenia, which was the purpose of this study. A group of 77 patients with schizophrenia had been recruited as part of a longitudinal study and were evaluated after their referral to nursing homes. Researchers compared ratings from the MDS with ratings of cognition and symptoms using instruments previously validated for the assessment of serious mental illness. The cognitive subscale of the MDS (MDS-COG) was not strongly correlated with the Mini-Mental State Examination and was generally uncorrelated with performance on neuropsychological tasks. Symptoms were underreported on the MDS and were not significantly associated with researchers' ratings. Moreover, the ratings from the MDS, unlike the researchers' ratings, were not predictive of functional status, revealing poor criterion validity. These findings suggest that the MDS is not a suitable rating instrument to evaluate the symptoms and functional characteristics of older patients with schizophrenia. Future work will be required to develop instruments that would allow nursing home staff to recognize and report symptoms, cognitive impairments, and functional characteristics of these patients, which are important first steps for improving treatment services.
- Top Cited Papers
- 1 March 2006
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 163 (3) , 418-425
Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms
Impairments in adaptive life skills are a major source of disability in patients with schizophrenia. The relationship between adaptive life skills in real-world settings and performance on neuropsychological tests may be complicated by other factors that interfere with deployment of skills. Assessment of the ability to perform life skills under optimal conditions (i.e., assessment of functional capacity) has been proposed as a means to clarify these relationships. The authors examined cross-sectional data from a study of the course of neuropsychological and adaptive life skills of older (age 50-85) schizophrenia patients (N=78). Functional capacity was examined with a performance-based measure (UCSD Performance-Based Skills Assessment), and case managers rated real-world adaptive functions (i.e., interpersonal skills, work skills, and community activities). Neuropsychological performance was assessed with a comprehensive battery, while symptoms were assessed with patient self-report and clinical ratings. Confirmatory path analyses were used to evaluate the effects of neuropsychological performance, functional capacity, and symptoms on the various domains of real-world functioning. Neuropsychological performance predicted functional capacity, which predicted all three domains of real-world functioning. Depression predicted interpersonal and work skills, while negative symptoms affected interpersonal skills independently of other predictors. Real-world adaptive life skills are predicted by neuropsychological performance, symptoms, and functional capacity. Neuropsychological performance contributes little to the prediction of real-world performance after accounting for functional capacity. In some domains, negative and depressive symptoms influenced real-world performance while not relating to functional capacity or neuropsychological performance.
- 1 March 2006
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 163 (3) , 418-425
Top Cited PapersDeterminants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms
Impairments in adaptive life skills are a major source of disability in patients with schizophrenia. The relationship between adaptive life skills in real-world settings and performance on neuropsychological tests may be complicated by other factors that interfere with deployment of skills. Assessment of the ability to perform life skills under optimal conditions (i.e., assessment of functional capacity) has been proposed as a means to clarify these relationships. The authors examined cross-sectional data from a study of the course of neuropsychological and adaptive life skills of older (age 50-85) schizophrenia patients (N=78). Functional capacity was examined with a performance-based measure (UCSD Performance-Based Skills Assessment), and case managers rated real-world adaptive functions (i.e., interpersonal skills, work skills, and community activities). Neuropsychological performance was assessed with a comprehensive battery, while symptoms were assessed with patient self-report and clinical ratings. Confirmatory path analyses were used to evaluate the effects of neuropsychological performance, functional capacity, and symptoms on the various domains of real-world functioning. Neuropsychological performance predicted functional capacity, which predicted all three domains of real-world functioning. Depression predicted interpersonal and work skills, while negative symptoms affected interpersonal skills independently of other predictors. Real-world adaptive life skills are predicted by neuropsychological performance, symptoms, and functional capacity. Neuropsychological performance contributes little to the prediction of real-world performance after accounting for functional capacity. In some domains, negative and depressive symptoms influenced real-world performance while not relating to functional capacity or neuropsychological performance.
- 1 December 2005
- Published by Springer Nature in Current Psychosis and Therapeutics Reports
- Vol. 3 (4) , 147-151
Cognitive impairment in schizophrenia spectrum personality
- 1 December 2005
- Published by Springer Nature in Current Psychosis and Therapeutics Reports
- Vol. 3 (4) , 147-151
Cognitive impairment in schizophrenia spectrum personality